It’s funny that they are fully funded all the way into phase 2 with non dilutive funding extending the companies funds well into phase 2 and the market cap is now trading below it’s coming up cash funding pricing nothing in for how de risked the drug is heading into phase 1 and phase 2 FDA approval. AGN is looking like on any good news will become a 200-300 million dollar company on the potential of the drug.
Ann: Significant Neuroprotection in NYR Preclinical Brain Injury, page-186
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.3¢ |
Change
-0.004(7.02%) |
Mkt cap ! $9.657M | |||
| Open | High | Low | Value | Volume |
| 5.6¢ | 5.6¢ | 5.3¢ | $4.061K | 75.46K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 140989 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 177449 | 3 |
View Market Depth
| Last trade - 15.54pm 26/07/2024 (20 minute delay) ? |
| NYR (ASX) Chart |